In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides

A. Capone; V. Cafiso; F. Campanile; G. Parisi; B. Mariani; N. Petrosillo; S. Stefani

doi:10.1007/s10096-016-2581-4

journal article Jan 27, 2016

In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides

A. Capone V. Cafiso F. Campanile G. Parisi B. Mariani N. Petrosillo S. Stefani

European Journal of Clinical Microbiology & Infectious Diseases Vol. 35 No. 4 pp. 625-631 · Springer Science and Business Media LLC

View at Publisher Save 10.1007/s10096-016-2581-4

Topics

No keywords indexed for this article. Browse by subject →

References

24

[1]

van Hal SJ, Lodise TP, Paterson DL (2012) The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 54:755–771 10.1093/cid/cir935

[2]

Yoon YK, Kim JY, Park DW et al (2010) Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother 65:1015–1018 10.1093/jac/dkq050

[3]

Lodise TP, Drusano GL, Lazariu V et al (2014) Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin. J Antimicrob Chemother 69:2547–2545 10.1093/jac/dku135

[4]

Mishra NN, Bayer AS, Weidenmaier C et al (2014) Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 16, e107426

[5]

Schweizer ML, Furuno JP, Sakoulas G et al (2011) Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 55:1082–1087 10.1128/aac.00918-10

[6]

Harigaya Y, Ngo D, Lesse AJ et al (2011) Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of Staphyloccocus aureus. BMC Infect Dis 11:287 10.1186/1471-2334-11-287

[7]

Cafiso V, Bertuccio T, Spina D et al (2012) A novel δ-hemolysis screening method for detecting heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate S. aureus. J Clin Microbiol 50:1742–1744 10.1128/jcm.06307-11

[8]

Chang SC, Liu TP, Chen CJ et al (2015) Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates using a combination of δ-hemolysis assay and Etest. Diagn Microbiol Infect Dis 81:246–250 10.1016/j.diagmicrobio.2014.12.006

[9]

Stefani S, Campanile F, Santagati M et al (2015) Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: a review of the available evidence. Int J Antimicrob Agents 46:278–289. doi: 10.1016/j.ijantimicag.2015.05.008 10.1016/j.ijantimicag.2015.05.008

[10]

Bayer AS, Schneider T, Sahl HG et al (2013) Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 1277:139–158 10.1111/j.1749-6632.2012.06819.x

[11]

Cafiso V, Bertuccio T, Purrello S et al (2014) dltA overexpression: a strain-independent keystone of daptomycin resistance in methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 43:26–31 10.1016/j.ijantimicag.2013.10.001

[12]

Mishra NN, Bayer AS, Weidenmaier C et al (2014) Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons. PLoS One 9, e107426

[13]

Kelley PG, Gao W, Ward PB et al (2011) Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 66:1057–1060 10.1093/jac/dkr066

[14]

Cafiso V, Bertuccio T, Spina D et al (2012) Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. PLoS One 7, e29573 10.1371/journal.pone.0029573

[15]

Campanile F, Bongiorno D, Borbone S et al (2009) Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy. Ann Clin Microbiol Antimicrob 8:22 10.1186/1476-0711-8-22

[16]

Stefani S, Bongiorno D, Cafiso V et al (2009) Pathotype and susceptibility profile of a community-acquired methicillin-resistant Staphylococcus aureus strain responsible for a case of severe pneumonia. Diagn Microbiol Infect Dis 63:100–104 10.1016/j.diagmicrobio.2008.09.012

[17]

Cafiso V, Bertuccio T, Santagati M et al (2007) agr-Genotyping and transcriptional analysis of biofilm-producing Staphylococcus aureus. FEMS Immunol Med Microbiol 51:220–227 10.1111/j.1574-695x.2007.00298.x

[18]

Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30, e36 10.1093/nar/30.9.e36

[19]

Matsuo M, Hishinuma T, Katayama Y et al (2011) Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Antimicrob Agents Chemother 55:4188–4195 10.1128/aac.00398-11

[20]

Cui L, Isii T, Fukuda M et al (2010) An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother 54:5222–5233 10.1128/aac.00437-10

[21]

Moise PA, North D, Steenbergen JN et al (2009) Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 9:617–624 10.1016/s1473-3099(09)70200-2

[22]

Bassetti M, Villa G, Ansaldi F et al (2015) Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients. Intensive Care Med 41:366–368 10.1007/s00134-014-3571-6

[23]

Wichelhaus T, Schäfer V, Brade V et al (2001) Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus. J Antimicrob Chemother 47:153–156 10.1093/jac/47.2.153

[24]

Smirnova MV, Vostrov SN, Strukova EV et al (2009) The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother 64:815–820 10.1093/jac/dkp287

Metrics

31

Citations

24

References

Details

Published: Jan 27, 2016
Vol/Issue: 35(4)
Pages: 625-631
License: View

Authors

Laboratoire de Physique Théorique et Modèles Statistiques, CNRS and Université Paris Sud, Bât. 100, 91405 Orsay Cedex, France.; Sezione INFN, SMC and UdRm1 of INFM, Università “La Sapienza,” P.le A. Moro 2, 00185 Roma, Italy.

Cite This Article

A. Capone, V. Cafiso, F. Campanile, et al. (2016). In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides. European Journal of Clinical Microbiology & Infectious Diseases, 35(4), 625-631. https://doi.org/10.1007/s10096-016-2581-4

In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides

You May Also Like